Literature DB >> 11854213

Cross-reactive polyclonal antibodies to the inner core of lipopolysaccharide from Neisseria meningitidis.

Svein Rune Andersen1, Terry Guthrie, Geoffrey R Guile, Jan Kolberg, Sam Hou, Lisa Hyland, Simon Y C Wong.   

Abstract

Sera from mice immunized with native or detergent-extracted outer membrane vesicles derived from lipopolysaccharide (LPS) mutant 44/76(Mu-4) of Neisseria meningitidis were analyzed for antibodies to LPS. The carbohydrate portion of 44/76(Mu-4) LPS consists of the complete inner core, Glc beta 1-->4[GlcNAc alpha 1-->2Hep alpha 1-->3]Hep alpha 1-->5KDO[4-->2 alpha KDO]. Immunoblot analysis revealed that some sera contained antibodies to wild-type LPS which has a fully extended carbohydrate chain of immunotype L3,7, as well as to the homologous LPS. Sera reacted only weakly to LPS from 44/76(Mu-3), which lacks the terminal glucose of the inner core. No binding to more truncated LPS was observed. Consequently, the cross-reactive epitopes are expressed mainly by the complete inner core. Dephosphorylation of wild-type LPS abolished antibody binding to LPS in all but one serum. Thus, at least two specificities of cross-reactive antibodies exist: one is dependent on phosphoethanolamine groups in LPS, and one is not. Detection of these cross-reactive antibodies strongly supports the notion that epitopes expressed by meningococcal LPS inner core are also accessible to antibodies when the carbohydrate chain is fully extended. Also, these inner core epitopes are sufficiently immunogenic to induce antibody levels detectable in polyclonal antibody responses. Meningococci can escape being killed by antibodies to LPS that bind only to a specific LPS variant, by altering the carbohydrate chain length. Cross-reactive antibodies may prevent such escape. Therefore, inner core LPS structures may be important antigens in future vaccines against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854213      PMCID: PMC127742          DOI: 10.1128/IAI.70.3.1293-1300.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis.

Authors:  D M Jones; R Borrow; A J Fox; S Gray; K A Cartwright; J T Poolman
Journal:  Microb Pathog       Date:  1992-09       Impact factor: 3.738

2.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Analysis of oligosaccharide epitopes of meningococcal lipopolysaccharides by fast-atom-bombardment mass spectrometry.

Authors:  A Dell; P Azadi; P Tiller; J Thomas-Oates; H J Jennings; M Beurret; F Michon
Journal:  Carbohydr Res       Date:  1990-04-25       Impact factor: 2.104

5.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis.

Authors:  A Gamian; M Beurret; F Michon; J R Brisson; H J Jennings
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

8.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

9.  Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.

Authors:  N Orr; G Robin; D Cohen; R Arnon; G H Lowell
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  2 in total

1.  Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.

Authors:  Maurílio F Santos; Roger R C New; Gabrielle R Andrade; Christiane Y Ozaki; Osvaldo A Sant'Anna; Lucia Mendonça-Previato; Luis R Trabulsi; Marta O Domingos
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

2.  Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis.

Authors:  Terry Guthrie; Simon Y C Wong; Bin Liang; Lisa Hyland; Sam Hou; E Arne Høiby; Svein Rune Andersen
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.